JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(3):182-187 | DOI: 10.36290/csf.2025.031

Case reports from individual consultations provided to patients in the pharmacy

Eliška Kolmanová1, 2, Josef Malý1, 3
1 Katedra sociální a klinické farmacie, Farmaceutická fakulta UK v Hradci Králové
2 Lékárny HERBA s.r.o.
3 Nemocniční lékárna, Fakultní nemocnice v Motole, Praha

The focus of pharmaceutical care is to optimise the patient's pharmacotherapy, aiming to maximise the effects and minimise the risks of treatment. In the pharmacy, the current legislation allows the pharmacist to carry out this activity not only in the context of dispensing activities, but also during the provision of individual counselling. This area of 'modern pharmaceutical care' is a more individualised form of expert advice, ideally carried out in a separate consulting room of the pharmacy through a structured conversation with a trained pharmacist. In addition to the management of drug-related problems in optimising pharmacotherapy, pharmacists in the Czech Republic are involved in screening for selected diseases, i.e. in the area of prevention. An undeniable advantage of providing individual counselling in the pharmacy is the time allocated for undisturbed communication with the patient, leading, among other things, to the establishment of trust and a better understanding of the patient's attitudes towards treatment. The content of the paper will include three case reports from the practice of a pharmacist involved in this area of pharmaceutical care. Specifically, it will address the practical attributes of optimizing pharmacotherapy in three geriatric patients and show a possible way to deal with them.

Keywords: pharmaceutical care, individual counselling in the pharmacy, adherence to treatment, drug-related problem.

Accepted: September 15, 2025; Published: October 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolmanová E, Malý J. Case reports from individual consultations provided to patients in the pharmacy. Čes. slov. farm. 2025;74(3):182-187. doi: 10.36290/csf.2025.031.
Download citation

References

  1. Malý J. Lékové problémy v teorii a příkladech v podmínkách České republiky. Klin Farmakol Farm. 2020;34(3):116-121. Go to original source...
  2. Vlček J, Fialová D, Malý J, et al. Koncepce oboru klinická farmacie I., vzdělávací část. Ceska Slov Farm. 2016; 65(Suppl):1-20.
  3. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555-567. Go to original source...
  4. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. Go to original source...
  5. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023;29(5):305-340. Go to original source...
  6. Mohan V, Saboo B, Khader J, et al. Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines. Clin Med Insights Endocrinol Diabetes. 2022;15:1-8. Go to original source...
  7. Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Healthy Longev. 2021;2(5):e290-300. Go to original source... Go to PubMed...
  8. Interactions. UpToDate Lexidrug. UpToDate Inc. Riverwoods, IL. [cited 2025 Jun 6].
  9. Drug Interactions. Merative Micromedex. Merative. Ann Arbor, MI. [cited 2025 Jun 6].
  10. Databáze lékových interakcí. Drug agency a.s. [cited 2025 Jun 6].
  11. Souhrn údajů o přípravku Pradaxa 150 mg. Datum revize 16/01/2024. [cited 2025 Jun 6]. Available from: http://www.sukl.cz.
  12. Guideline for the pharmacological treatment of hypertension in adults [Internet]. Geneva: World Health Organization; 2021. [cited 2025 Jun 6]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK573631/
  13. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Vnitr Lek. 2018;7-8:771-796.
  14. Málek F, Veselý J, Pudil R, et al. Souhrn Doporučených postupů Evropské kardiologické společnosti pro diagnostiku a léčbu srdečního selhání z roku 2021. Cor Vasa 2022;64:121-162. Go to original source...
  15. Málek F, Veselý J, Pudil R, et al. Doporučení ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání 2021: Překlad zkráceného dokumentu připravený Českou kardiologickou společností. Cor Vasa 2022;64(3):4-55. Go to original source...
  16. Haastrup PF, Jarbøl DE, Thompson W, et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol. 2021;8(1):1-10. Go to original source... Go to PubMed...
  17. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2018;10:1-13. Go to original source... Go to PubMed...
  18. Souhrn údajů o přípravku Betaserc 24 mg. Datum revize 14/06/2022. [cited 2025 Jun 6]. Available from: http://www.sukl.cz.
  19. Dusilová Sulková S. Nezastupitelná úloha vitaminu D v prevenci a léčbě osteoporózy. Prakt. lékáren. 2011; 7(2): 58-61.
  20. Topinková E, Matějková A. Geriatrie: doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře 2024. Praha: Centrum doporučených postupů pro praktické lékaře, Společnost všeobecného lékařství, 2024. [cited 2025 Aug 10]. Available from: https://svl.cz/doporucene-postupy/geriatrie-100032.
  21. Cífková R, Vaverková H, Filipovský J, et al. Souhrn Evropských doporučení pro prevenci kardiovaskulárních onemocnění v klinické praxi (verze 2012). Připraven Českou kardiologickou společností. Cor Vasa. 2014;56(2):e169-189. Go to original source...
  22. Karetová D, Vojtíšková J, Roztočil K. Ischemická choroba dolních končetin: doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře Novelizace 2016. Doporučené postupy pro praktické lékaře. Praha: Centrum doporučených postupů pro praktické lékaře, 2016. [cited 2025 Jun 12]. Available from: https://svl.cz/svl-docs/doporucene-postupy/29/ischemicka-choroba-dolnich-koncetin-2016.pdf.
  23. Koblížek V, Zatloukal J, Konšatecký S. Chronická obstrukční plicní nemoc: doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře 2019. Praha: Centrum doporučených postupů pro praktické lékaře, Společnost všeobecného lékařství, 2019. [cited 2025 Jun 12]. Available from: https://svl.cz/svl-docs/doporucene-postupy/39/chronicka-obstrukcni-plicni-nemoc-2019.pdf.
  24. Wilcox CS, Shen W, Boulton DW, et al. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J Am Heart Assoc. 2018;7(4):e007046. Go to original source... Go to PubMed...
  25. Prieto-García L, Pericacho M, Sancho-Martínez SM, et al. Mechanisms of triple whammy acute kidney injury. Pharmacol Ther. 2016;167:132-145. Go to original source... Go to PubMed...
  26. Ferreri SP, Hughes TD, Snyder ME. Medication Therapy Management: Current Challenges. Integr Pharm Res Pract. 2020;2(9):71-81. Go to original source... Go to PubMed...
  27. Al-Babtain B, Cheema E, Hadi MA. Impact of community-pharmacist-led medication review programmes on patient outcomes: A systematic review and meta-analysis of randomised controlled trials. Res Social Adm Pharm. 2022;18(4):2559-2568. Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.